Latest Strategy News

EBOS Group Limited reported a solid 13% increase in revenue for the first half of FY2026, alongside a 13% rise in net profit attributable to owners, while maintaining its interim dividend.

Acrow Ltd reported a robust 23% revenue increase in 1H FY26, driven by its expanding Industrial Access division, even as net profit fell 22% amid Queensland market softness. The company’s strategic investments and acquisitions position it well for future growth.

Magontec Limited reported a net loss of $5.4 million for 2025 on a 10.9% drop in revenue, yet net tangible assets per share rose significantly to 76 cents.

Metro has announced a significant share consolidation, reducing its total shares on issue from nearly 984 million to approximately 24.6 million. The move aims to streamline the capital structure ahead of trading resumption in early March.

Timah Resources Limited reported a 24% revenue decline and a narrow profit turnaround in 2025, overcoming a lengthy biogas plant shutdown caused by a critical equipment failure. Operational efficiency gains and risk mitigation efforts underpin the company’s cautious optimism.

Euroz Hartleys Group Limited reported a robust half-year result for December 2025, with net profit more than doubling to $13.84 million, driven by strong growth in equity capital markets and advisory fees.

Thorney Technologies reported a sharply reduced half-year profit amid challenging market conditions but extended its share buyback to support shareholder value.

Orcoda Limited has reported strong half-year FY26 results, showcasing significant growth in revenue, EBITDA, and recurring revenue as it advances its AI-powered transport ecosystem solutions.

SolGold shareholders have approved the recommended cash acquisition by Jiangxi Copper, a move that directly impacts DGR Global’s substantial investment in the company. Completion awaits court approval and further conditions.

Papyrus Australia Limited reported a reduced half-year loss and marked a significant commercial milestone with a $4.2 million supply contract, advancing its transition from technology development to early-stage commercialisation.

TrivarX Limited reported a $1.26 million half-year loss as it completed the acquisition of Stabl-Im brain imaging IP and validated its mental health screening technology in veterans. The company raised $4.2 million to fund clinical development and expand its diagnostic portfolio.

333D Limited reported a 23% increase in revenue to $588,678 for the half-year ended December 2025, despite a 92% plunge in profit after tax to a $282,030 loss. The company boosted its cash reserves significantly and initiated a strategic Bitcoin investment.